Epirubicin
Drug · tier A · 8 trials (1 recruiting) · 14 publications · score 76.5
Olaparib
Drug · tier A · 8 trials (2 recruiting) · 18 publications · score 73.0
Sacituzumab Govitecan
Drug · tier A · 8 trials (4 recruiting) · 15 publications · score 73.0
Vinorelbine
Drug · tier A · 8 trials (1 recruiting) · 16 publications · score 73.0
Cisplatin
Drug · tier A · 8 trials (1 recruiting) · 16 publications · score 72.5
Tamoxifen Citrate
Drug · tier A · 8 trials (0 recruiting) · 8 publications · score 72.0
Gemcitabine
Drug · tier A · 8 trials (0 recruiting) · 17 publications · score 70.5
Talazoparib
Drug · tier A · 8 trials (1 recruiting) · 20 publications · score 70.0
Rucaparib
Drug · tier A · 8 trials (0 recruiting) · 10 publications · score 68.5
Carboplatin
Drug · tier A · 8 trials (2 recruiting) · 14 publications · score 67.0
Oxaliplatin
Drug · tier A · 8 trials (0 recruiting) · 14 publications · score 63.0
Doxorubicin Hydrochloride
Drug · tier A · 8 trials (1 recruiting) · 6 publications · score 56.0
Bicalutamide
Drug · tier A · 8 trials (2 recruiting) · 3 publications · score 54.5
Mitomycin
Drug · tier A · 4 trials (0 recruiting) · 8 publications · score 54.0
Mitoxantrone Hydrochloride
Drug · tier A · 8 trials (1 recruiting) · 5 publications · score 50.5
Paclitaxel Protein-Bound
Drug · tier A · 8 trials (1 recruiting) · 3 publications · score 48.0
Sirolimus
Drug · tier A · 8 trials (1 recruiting) · 3 publications · score 47.0
Resveratrol
Drug · tier A · 3 trials (0 recruiting) · 8 publications · score 46.5
Riboflavin
Drug · tier A · 2 trials (0 recruiting) · 6 publications · score 40.5
Daunorubicin Hydrochloride
Drug · tier A · 8 trials (0 recruiting) · 0 publications · score 40.0
Flumazenil
Drug · tier A · 1 trials (0 recruiting) · 2 publications · score 26.5
Dipyridamole
Drug · tier A · 0 trials (0 recruiting) · 3 publications · score 26.0
Methoxsalen
Drug · tier A · 2 trials (1 recruiting) · 0 publications · score 25.0
Research map, not treatment advice. Built 2026-10-07.